CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −222 | $471.25 | $105K | 8,403 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −823 | $472.82 | $389K | 7,580 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −838 | $474.22 | $397K | 6,742 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −951 | $474.85 | $452K | 5,791 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −972 | $476.31 | $463K | 4,819 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,183 | $477.47 | $565K | 3,636 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,450 | $478.67 | $694K | 2,186 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,386 | $479.55 | $665K | 800 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −25 | $480.98 | $12K | 775 |
| 2025-09-09 | Reitan Colleen F Director | Option exercise · Stock Option (right to buy) 10b5-1 | −18,000 | 0 | ||
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −195 | $445.53 | $87K | 29,271 |
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −899 | $446.98 | $402K | 28,372 |
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −1,289 | $448.05 | $578K | 27,083 |
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −681 | $449.54 | $306K | 26,402 |
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −266 | $451.52 | $120K | 26,136 |
| 2025-08-29 | Tanguler Tolga EVP, Chief Commercial Officer | Sale 10b5-1 | −144 | $452.49 | $65K | 25,992 |
| 2025-08-19 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −276 | $455.41 | $126K | 21,400 |
| 2025-08-19 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −338 | $457.26 | $155K | 21,062 |
| 2025-08-19 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −231 | $458.27 | $106K | 20,831 |
| 2025-08-19 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −260 | $459.59 | $119K | 20,571 |
Page 23 of 41 · 816 trades